StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 7/30
$165.00−9.00 (-5.17%)

Close on Oct 30, 2026Market cap $22.08BP/E –Yield –

Earnings

Alnylam Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.46B
+16.7% on a year earlier
Non-GAAP Net income per common share — diluted, Q3 FY2026
$16.26
$2.90 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Alnylam Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026before the open$1.46B+16.7%$15.72$16.26Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026before the open––––Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026before the open$1.17B–$1.51$1.99Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026before the open$1.10B–$0.82$1.25Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025before the open$1.25B–$1.84$2.90Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$773.69M–-$0.51$0.32Release
Q4 FY2024ended Dec 31, 2024Jan 13, 2025before the open––––Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024before the open$439.72M+31.2%-$1.10-$0.77Release
Q3 FY2023ended Sep 30, 2023Nov 2, 2023before the open$750.53M+184.0%$1.15$1.74Release
Q2 FY2023ended Jun 30, 2023Aug 3, 2023before the open$318.75M+41.8%-$2.21-$1.62Release
Q1 FY2023ended Mar 31, 2023May 4, 2023before the open$319.29M+49.7%-$1.40-$1.06Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Alnylam Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net product revenues growth vs. 2025 at constant exchange ratesnon-GAAPFY2026+57% – +70%+64% – +77%LoweredOct 29, 2026
Net product revenues growth vs. 2025 at constant exchange ratesnon-GAAPFY2026+64% – +77%–NewApr 30, 2026
Net product revenues growth vs. 2025 at currency exchange rates as of December 31, 2025FY2026+64% – +77%–NewApr 30, 2026
Net product revenues growth vs. 2025 at currency exchange rates as of June 30, 2026FY2026+57% – +71%+64% – +77%LoweredOct 29, 2026
Total TTR net product revenues (AMVUTTRA, ONPATTRO)FY2026$4.20B – $4.50B$4.40B – $4.70BRaisedOct 29, 2026
Total TTR net product revenues (AMVUTTRA, ONPATTRO)FY2026$4.40B – $4.70B$4.90B – $5.30BRaisedApr 30, 2026
Non-GAAP R&D and SG&A expensesnon-GAAPFY2026$2.70B – $2.80B$2.70B – $2.80BReaffirmedOct 29, 2026
Non-GAAP R&D and SG&A expensesnon-GAAPFY2026$2.70B – $2.80B–NewApr 30, 2026

Guidance history

Every forecast Alnylam Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026Non-GAAP R&D and SG&A expensesFY2026$2.70B – $2.80BReaffirmed
Oct 29, 2026Net product revenues growth vs. 2025 at currency exchange rates as of June 30, 2026FY2026+57% – +71%Lowered
Oct 29, 2026Net product revenues growth vs. 2025 at constant exchange ratesFY2026+57% – +70%Lowered
Oct 29, 2026Total TTR net product revenues (AMVUTTRA, ONPATTRO)FY2026$4.20B – $4.50BRaised
Oct 29, 2026Total Rare net product revenues (GIVLAARI, OXLUMO)FY2026$500.00M – $600.00MLowered
Oct 29, 2026Total net product revenuesFY2026$4.70B – $5.10BRaised
Oct 29, 2026Net revenues from collaborations and royaltiesFY2026$575.00M – $625.00MLowered
Apr 30, 2026Non-GAAP R&D and SG&A expensesFY2026$2.70B – $2.80BNew
Apr 30, 2026Net product revenues growth vs. 2025 at currency exchange rates as of December 31, 2025FY2026+64% – +77%New
Apr 30, 2026Net product revenues growth vs. 2025 at constant exchange ratesFY2026+64% – +77%New
Apr 30, 2026Total TTR net product revenues (AMVUTTRA, ONPATTRO)FY2026$4.40B – $4.70BRaised
Apr 30, 2026Total Rare net product revenues (GIVLAARI, OXLUMO)FY2026$500.00M – $600.00MLowered
Apr 30, 2026Total net product revenuesFY2026$4.90B – $5.30BRaised
Apr 30, 2026Net revenues from collaborations and royaltiesFY2026$400.00M – $500.00MLowered
Feb 12, 2026Non-GAAP R&D and SG&A expensesFY2026$2.70B – $2.80BNew
Feb 12, 2026Net product revenues growth vs. 2025 at currency exchange rates as of December 31, 2025FY2026+64% – +77%New
Feb 12, 2026Net product revenues growth vs. 2025 at constant exchange ratesFY2026+64% – +77%New
Feb 12, 2026Total TTR net product revenues (AMVUTTRA, ONPATTRO)FY2026$4.40B – $4.70BNew
Feb 12, 2026Total Rare net product revenues (GIVLAARI, OXLUMO)FY2026$500.00M – $600.00MLowered
Feb 12, 2026Net revenues from collaborations and royaltiesFY2026$400.00M – $500.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Alnylam Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress
    Results
  2. Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
    Results
  3. Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
    Results
  4. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
    Results
  5. Alnylam Launches “ Alnylam 2030 ” Strategy to Drive Next Era of Growth and Patient Impact
    Results
  6. Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
    News
  7. Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
    Results
  8. Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
    News
  9. Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
    News
  10. Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
    Results
  11. 8-K exhibit EX-99.1
    News
  12. Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
    Results
  13. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
    Results
  14. Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides
    Results
  15. Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
    Results